TAZAROTENE (tazarotene) by Design Pharmaceuticals is form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Approved for retinoid [epc]. First approved in 2022.
Drug data last refreshed 18h ago
form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical…
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Worked on TAZAROTENE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.